[Experimental studies of the nephroprotective effect of fosfomycin].
We studied in an experimental rat model, if fosfomycin reduces the tubulotoxicity induced by tobramycin, teicoplanin, cisplatin or ciclosporine A and is thus a nephroprotective agent. 10 female wistar rats per dose and compound were used, measures of tubulotoxicity were urinary excretion rates of tubular cells and malate dehydrogenase on 5 successive days. Fosfomycin proved to be a potent nephroprotector against all 4 nephrotoxins. Its activity was not based on pharmacokinetic interactions but on a pharmacodynamic effect. Presumably, fosfomycin stabilises the membranes of lysosomes in tubular cells.
D058186:Acute Kidney Injury / Q000517:prevention & control*; D000818:Animals; D002945:Cisplatin / Q000633:toxicity; D003524:Cyclosporins / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D005260:Female; D005578:Fosfomycin / Q000627:therapeutic use*; D006020:Glycopeptides / Q000633:toxicity; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced / Q000517:prevention & control*; D007684:Kidney Tubules / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D017334:Teicoplanin; D014031:Tobramycin / Q000633:toxicity
D003524:Cyclosporins; D006020:Glycopeptides; D005578:Fosfomycin; D017334:Teicoplanin; D002945:Cisplatin; D014031:Tobramycin
Experimentelle Untersuchungen zur nephroprotektiven Wirkung von Fosfomycin.